期刊
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
卷 161, 期 -, 页码 -出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.critrevonc.2021.103325
关键词
PhotoImmunoTherapy; Near-InfraRed fluorophores; Monoclonal antibodies; Solid cancers; Local control; In vivo; In vitro; Clinical trials
资金
- Medical Research Council UK Clinical Academic Research Partnership [MR/T005491/1]
- Wellcome/EPSRC Centre for Interventional and Surgical Sciences (WEISS) at the University College London, United Kingdom [203145Z/16/Z]
NIR-PIT is a novel cancer-targeted treatment that involves a chemical conjugation between a photosensitiser and a cancer-targeting moiety, leading to accumulation at the tumor cell surface and targeted cell death upon NIR-light irradiation. While the mechanisms of action are not fully understood, researchers are working to address key unanswered research questions.
Near-InfraRed PhotoImmunoTherapy (NIR-PIT) is a novel cancer-targeted treatment effected by a chemical conjugation between a photosensitiser (e.g. the NIR phthalocyanine dye IRDye700DX) and a cancer-targeting moiety (e.g. a monoclonal antibody, moAb). Delivery of a conjugate in vivo leads to accumulation at the tumour cell surface by binding to cell surface receptors or antigens. Upon deployment of focal NIR-light, irradiation of the conjugate results in a rapid, targeted cell death. However, the mechanisms of action to produce the cytotoxic effects have yet to be fully understood. Herein, we bring together the current knowledge of NIR-PIT from preclinical and clinical studies in a variety of cancers highlighting the key unanswered research questions. Furthermore, we discuss how to enhance the local control of solid cancers using this novel treatment regimen.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据